Peuskens 1995.

Methods	Allocation: randomised (random permuted block procedure with randomisation list transferred to sealed envelopes). Blindness: double (no further description). Duration: 8 weeks (preceded by one week washout). Consent: not stated. Setting: multi‐centre, multi‐national.
Participants	Diagnosis: schizophrenia (DSM‐III‐R). N=1362. Age: mean ˜ 38 years. Sex: 894M, 467F. History: chronic, mean duration of illness ˜17 years, Exclusions: PANSS score < 60
Interventions	1. Risperidone: 1mg/day. N=229. 2. Risperidone: 4mg/day. N=227. 3. Risperidone: 8mg/day. N=230. 4. Risperidone: 12mg/day. N=226. 5. Risperidone: 16mg/day. N=224. 6. Haloperidol: 10mg/day. N=226. Medication titrated to fixed maintainance dose during week
Outcomes	Clinical improvement: 20% reduction PANSS. Mental state:BPRS ‐ PANSS derived, PANSS. Adverse effects: CGI, ESRS, modified UKU, use of antiparkinsonian medication. Leaving the study early. Unable to use ‐ Physiological monitoring: ECG, lab tests (no data).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate